Literature DB >> 11356903

3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.

M G Bankson1, K A Cunningham.   

Abstract

(+)-3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy"; "X"; "E") is a popular recreational amphetamine analog that produces a unique set of effects in humans and animals. MDMA use is often associated with dance parties called "raves", but its use has increased in all segments of society and around the world. Like amphetamine, MDMA elicits hyperactivity when administered to rodents. Unlike amphetamine, which has effects mediated by the release of dopamine (DA) from nerve terminals, MDMA-induced hyperactivity is thought to be dependent upon the release of 5-hydroxtryptamine (5-HT). However, MDMA elicits large increases in synaptic concentrations of both DA and 5-HT, and the interaction between these neurotransmitters may account for the unique characteristics of the drug. Comparisons between MDMA, the selective DA releaser amphetamine, and the selective 5-HT releaser fenfluramine are used in the present discussion to highlight the ability of MDMA to model the locomotor activation induced by the interaction of DA and 5-HT. Furthermore, this review summarizes evidence to suggest that the influence of 5-HT receptors on behavioral function is dependent upon the specific neurochemical environment evoked by a given drug, specifically discussed here with regard to the interaction between 5-HT and DA systems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356903

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  Investigation of the mechanisms mediating MDMA "Ecstasy"-induced increases in cerebro-cortical perfusion determined by btASL MRI.

Authors:  J Rouine; M E Kelly; C Jennings-Murphy; P Duffy; I Gorman; S Gormley; C M Kerskens; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2014-11-01       Impact factor: 4.530

2.  Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Authors:  Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

3.  Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study.

Authors:  John Karageorgiou; Mary S Dietrich; Evonne J Charboneau; Neil D Woodward; Jennifer U Blackford; Ronald M Salomon; Ronald L Cowan
Journal:  Neuroimage       Date:  2009-03-02       Impact factor: 6.556

4.  The orexin-1 receptor antagonist SB-334867 decreases sympathetic responses to a moderate dose of methamphetamine and stress.

Authors:  Daniel E Rusyniak; Dmitry V Zaretsky; Maria V Zaretskaia; Pamela J Durant; Joseph A DiMicco
Journal:  Physiol Behav       Date:  2012-02-14

5.  Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats.

Authors:  Charles W Schindler; Eric B Thorndike; Bruce E Blough; Srihari R Tella; Steven R Goldberg; Michael H Baumann
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

6.  Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users.

Authors:  Ronald L Cowan; Nicolas R Bolo; Mary Dietrich; Erica Haga; Scott E Lukas; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2007-06-18       Impact factor: 3.222

Review 7.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

8.  Attenuation of ecstasy-induced neurotoxicity by N-acetylcysteine.

Authors:  Sara Soleimani Asl; Bita Saifi; Abolhasan Sakhaie; Somayeh Zargooshnia; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2014-08-06       Impact factor: 3.584

9.  Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice.

Authors:  Stéphane Doly; Jesus Bertran-Gonzalez; Jacques Callebert; Alexandra Bruneau; Sophie Marie Banas; Arnauld Belmer; Katia Boutourlinsky; Denis Hervé; Jean-Marie Launay; Luc Maroteaux
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

10.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.